Lithuanian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
5 rezultatus
[Trial of a new synthetic fluidifying and analeptic agent: sobrerol. Its use in inflammatory bronchopneumopathies].
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Action of sobrerol on mucociliary transport.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Some pharmacological properties of Sobrerol have been assessed, in frog palate preparation, by measuring the mucociliary transport velocity due to mucus samples obtained for patients suffering from chronic bronchial inflammatory diseases characterized by dense bronchial secretions. The patients were
The human nasal mucous membrane during chronic inflammation, before and after muco-active therapy: a study using scanning electron microscopy.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
Chronic inflammation seems to induce alterations in nasal mucosa morphology. The type and extent of these alterations seem to be directly correlated with the duration of the inflammation. This study was carried out to ascertain whether the administration of muco-active drugs could modify these
Evaluation of the efficacy and safety of sobrerol granules in patients suffering from chronic rhinosinusitis.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
In a double-blind, randomized, placebo-controlled clinical trial, the safety and efficacy of 900 mg/day sobrerol granules given for up to 10 days was assessed in 40 patients with chronic catarrhal rhinosinusitis. At the beginning of treatment a total of six patients had a fever, whereas body
2-(2,3-Dihydro-5-acetoxy-4,6,7-tribenzofuranyl)acetic acid (IRFI 016): a new antioxidant mucoactive drug.
Straipsnius versti gali tik registruoti vartotojai
Prisijungti Registracija
IRFI 016 has demonstrated significant antioxidant activity, inhibiting hepatic lipid peroxidation (rat intoxicated by CCl4) and the formation of gastric lesions by ethanol (rat). This activity proved equal to or better than that exhibited by the most investigated antioxidant/radical scavenger agents
Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu
- Dirba 55 kalbomis
- Žolelių gydymas, paremtas mokslu
- Vaistažolių atpažinimas pagal vaizdą
- Interaktyvus GPS žemėlapis - pažymėkite vaistažoles vietoje (netrukus)
- Skaitykite mokslines publikacijas, susijusias su jūsų paieška
- Ieškokite vaistinių žolelių pagal jų poveikį
- Susitvarkykite savo interesus ir sekite naujienas, klinikinius tyrimus ir patentus
Įveskite simptomą ar ligą ir perskaitykite apie žoleles, kurios gali padėti, įveskite žolę ir pamatykite ligas bei simptomus, nuo kurių ji naudojama.
* Visa informacija pagrįsta paskelbtais moksliniais tyrimais
